The results of the present study indicate that DAPK1 methylation may be involved in imatinib resistance in CML depending on the type of BCR-ABL mutation; however, DAPK1 may not have a direct effect on the suppression of overexpressed tyrosine kinase in CML patients. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.